Trial Profile
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Prodromal to Mild Alzheimer's Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2023
Price :
$35
*
At a glance
- Drugs Semorinemab (Primary) ; Florbetapir F 18
- Indications Alzheimer's disease
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms TAURIEL
- Sponsors Genentech
- 20 Jul 2023 Results from CREAD, CREAD2 and Tauriel; assessing assess the additive prognostic value of including baseline [18F]GTP1 tau-PET with the other common predictors presented at the Alzheimer's Association International Conference 2023.
- 09 Nov 2022 Results from CREAD, CREAD2 and Tauriel; assessing independence in activities of daily living in People With Early Alzheimers Disease, presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 04 Aug 2022 Results of evaluation of Longitudinal [18F]GTP1 Tau Burden Metrics, presented at the Alzheimer's Association International Conference 2022